ENVARSUS Drug Patent Profile
✉ Email this page to a colleague
When do Envarsus patents expire, and when can generic versions of Envarsus launch?
Envarsus is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are ten patents protecting this drug.
The generic ingredient in ENVARSUS is tacrolimus. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Envarsus
A generic version of ENVARSUS was approved as tacrolimus by SANDOZ on August 10th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ENVARSUS?
- What are the global sales for ENVARSUS?
- What is Average Wholesale Price for ENVARSUS?
Summary for ENVARSUS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ENVARSUS |
| What excipients (inactive ingredients) are in ENVARSUS? | ENVARSUS excipients list |
| DailyMed Link: | ENVARSUS at DailyMed |
US Patents and Regulatory Information for ENVARSUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | 8,664,239 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | 10,166,190 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | 9,549,918 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | 12,403,095 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | 8,664,239 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | 11,110,081 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
